BR9205961A - Composição farmacêutica para a prevenção e/ou tratamento de processos patológicos, processo de usar uma heparina de baixo peso molecular para a preparação de uma composição farmacêutica e processo de tratar uma pessoa que sofre de um processo patológico - Google Patents

Composição farmacêutica para a prevenção e/ou tratamento de processos patológicos, processo de usar uma heparina de baixo peso molecular para a preparação de uma composição farmacêutica e processo de tratar uma pessoa que sofre de um processo patológico

Info

Publication number
BR9205961A
BR9205961A BR9205961A BR9205961A BR9205961A BR 9205961 A BR9205961 A BR 9205961A BR 9205961 A BR9205961 A BR 9205961A BR 9205961 A BR9205961 A BR 9205961A BR 9205961 A BR9205961 A BR 9205961A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pathological
prevention
molecular weight
treatment
Prior art date
Application number
BR9205961A
Other languages
English (en)
Inventor
Irun R Cohen
Ofer Lider
Rami Hershkoviz
Original Assignee
Yeda Res & Dev
Cohen Yrun R
Ofer Lider
Rami Hershkoviz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9802891A external-priority patent/IL98028A/en
Priority claimed from IL98298A external-priority patent/IL98298A0/xx
Application filed by Yeda Res & Dev, Cohen Yrun R, Ofer Lider, Rami Hershkoviz filed Critical Yeda Res & Dev
Publication of BR9205961A publication Critical patent/BR9205961A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
BR9205961A 1991-05-02 1992-05-01 Composição farmacêutica para a prevenção e/ou tratamento de processos patológicos, processo de usar uma heparina de baixo peso molecular para a preparação de uma composição farmacêutica e processo de tratar uma pessoa que sofre de um processo patológico BR9205961A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL9802891A IL98028A (en) 1991-05-02 1991-05-02 Pharmaceutical compositions comprising a low molecular weight heparin (LMWH)
IL98298A IL98298A0 (en) 1991-05-28 1991-05-28 Pharmaceutical compositions comprising a heparin derivative
PCT/US1992/003626 WO1992019249A1 (en) 1991-05-02 1992-05-01 Compositions for the prevention and/or treatment of pathological processes

Publications (1)

Publication Number Publication Date
BR9205961A true BR9205961A (pt) 1994-07-26

Family

ID=26322260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9205961A BR9205961A (pt) 1991-05-02 1992-05-01 Composição farmacêutica para a prevenção e/ou tratamento de processos patológicos, processo de usar uma heparina de baixo peso molecular para a preparação de uma composição farmacêutica e processo de tratar uma pessoa que sofre de um processo patológico

Country Status (15)

Country Link
US (3) US5474987A (pt)
EP (1) EP0583360B1 (pt)
JP (1) JPH06507635A (pt)
KR (1) KR100235782B1 (pt)
AT (1) ATE217796T1 (pt)
AU (1) AU668865B2 (pt)
BR (1) BR9205961A (pt)
CA (1) CA2102207A1 (pt)
CZ (1) CZ232593A3 (pt)
DE (1) DE69232615T2 (pt)
FI (1) FI934849A7 (pt)
HU (1) HUT67136A (pt)
NO (1) NO933942L (pt)
SK (1) SK120193A3 (pt)
WO (1) WO1992019249A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
HUT70945A (en) * 1992-11-10 1995-11-28 Yeda Res & Dev Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
UA63929C2 (uk) * 1996-11-27 2004-02-16 Aventis Pharm Prod Inc Фармацевтична композиція та продукт, що містить сполуки з анти-ха активністю і антагоніст агрегації тромбоцитів, спосіб і набір для лікування або профілактики захворювань, які супроводжують тромбоутворення
AU756279B2 (en) * 1997-07-14 2003-01-09 Medical Therapies Limited Agents comprising Midkine or its inhibitor as active ingredient
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (ja) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
CA2377734A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
CA2402160C (en) * 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
CA2420890A1 (en) * 2000-09-08 2002-03-14 Hamilton Civic Hospitals Research Development, Inc. Antithrombotic compositions
DE60138115D1 (de) * 2000-09-12 2009-05-07 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002221935A1 (en) * 2000-12-16 2002-06-24 Aventis Pharma Deutschland Gmbh Use of low molecular heparin for treating osteoarthritis
CA2451245A1 (en) * 2001-06-25 2003-01-03 Depuy International Limited Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
WO2003011119A2 (en) * 2001-07-31 2003-02-13 Reddy Us Therapeutics, Inc. Methods and compositions for diagnosis and treatment of vascular conditions
CA2455038A1 (en) * 2001-07-31 2003-02-13 Board Of Regents, University Of Texas System Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
EP1542704A1 (en) * 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1592373B1 (en) 2003-01-30 2013-04-24 ProChon Biotech Ltd. Freeze-dried fibrin matrices and methods for preparation thereof
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
EP2399990B1 (en) 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US7560444B2 (en) * 2003-10-01 2009-07-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
US20060293275A1 (en) * 2004-03-29 2006-12-28 Toshikazu Nakamura Hgf production accelerator containing heparin-like oligosaccharide
WO2006023487A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Rapid two-step synthesis of anti-coagulants
CA2589041C (en) 2004-12-23 2019-08-20 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
ZA200801696B (en) * 2005-07-22 2009-08-26 Univ California Heparin compositions and selection inhibition
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
AU2009250803A1 (en) * 2008-05-20 2009-11-26 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
EP0114589B1 (en) * 1982-12-20 1987-09-23 The President And Fellows Of Harvard College Inhibition of angiogenesis
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
US4889808A (en) * 1985-10-01 1989-12-26 American Home Products Method of enchancing t-PA and SCU-PA production
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
US4788307A (en) * 1986-04-30 1988-11-29 Choay S.A. Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity
EP0245813B2 (en) * 1986-05-16 2000-03-22 ITALFARMACO S.p.A. EDTA-free heparins, heparin fractions and fragments, processes for their preparation and pharmaceutical compositions containing them
WO1988000017A1 (en) * 1986-06-27 1988-01-14 Boon Corporation Pty. Ltd. Mat
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
AT500533B8 (de) * 2000-04-13 2007-02-15 Man Nutzfahrzeuge Ag Gas- oder trolleybus

Also Published As

Publication number Publication date
FI934849A0 (fi) 1993-11-02
WO1992019249A1 (en) 1992-11-12
HU9303110D0 (en) 1994-01-28
EP0583360B1 (en) 2002-05-22
AU1913192A (en) 1992-12-21
DE69232615D1 (de) 2002-06-27
EP0583360A4 (pt) 1994-04-06
US5474987A (en) 1995-12-12
AU668865B2 (en) 1996-05-23
CZ232593A3 (en) 1994-07-13
US5686431A (en) 1997-11-11
SK120193A3 (en) 1994-07-06
FI934849A7 (fi) 1993-12-31
DE69232615T2 (de) 2003-01-30
NO933942L (no) 1993-12-14
HUT67136A (en) 1995-02-28
NO933942D0 (no) 1993-11-01
US5908837A (en) 1999-06-01
JPH06507635A (ja) 1994-09-01
KR100235782B1 (ko) 1999-12-15
CA2102207A1 (en) 1992-11-03
EP0583360A1 (en) 1994-02-23
ATE217796T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
BR9205961A (pt) Composição farmacêutica para a prevenção e/ou tratamento de processos patológicos, processo de usar uma heparina de baixo peso molecular para a preparação de uma composição farmacêutica e processo de tratar uma pessoa que sofre de um processo patológico
ES2192667T3 (es) Tratamiento de los trastornos de la artritis, artritis reumatica y manifestaciones asociadas con los trastornos reumaticos.
DK0781278T3 (da) Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse
PT977564E (pt) Forscolina para promocao da massa corporal magra
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
HUT77380A (hu) Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
DE69033970D1 (de) Huperzin a analoge verbindungen
HUP9601798A1 (hu) Kappa-ópium agonista hatású pirrolidinszármazékokat tartalmazó gyógyszerkészítmények bélgyulladások kezelésére
MX2024014216A (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados
ATE170399T1 (de) Zusammensetzung und verfahren zur behandlung viraler infektionen
EE9900044A (et) Farmatseutilised tooted veresoonte endoteelirakkude kahjustuste tagajärjel tekkinud haiguste raviks ja vältimiseks
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ATE201601T1 (de) Pharmazeutische zusammensetzungen enthaltend ein neutralisiertes virus, und verwendung derselben
WO2015023147A1 (ko) mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
MX2022011188A (es) Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.
Mateo-Casas et al. Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
UA74335C2 (uk) Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
BR9815617A (pt) Compostos substituìdos de 11-fenil-dibenzazepina, composição farmacêutica baseada nos referidos compostos, e métodos para inibir a proliferação de células de mamìferos e para tratamento ou prevenção de desordem causada por proliferação anormal de células
Peters et al. Pattern of macrophage subpopulations in post-traumatic bone infections after combined operativelantibiotic treatment
Hubbard et al. TISSUE FACTOR-FACTOR VII INHIBITION REQUIRES FACTOR Xa AND PLASMA LIPOPROTEINS.

Legal Events

Date Code Title Description
EE Request for examination
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/715 (2006.01), A61K 31/7016 (2006.0